Diligence memo · auto-generated · as of July 2, 2026
Plurogen Therapeutics Inc
Plurogen Therapeutics Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Plurogen Therapeutics Inc operates in Biotechnology, based in NORRISTOWN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Plurogen Therapeutics Inc has raised $1.7M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.2M on 2011-11-03.
Most recent recorded round closed around 2014-04-04.
Valuation (modeled)modeled
Provath models Plurogen Therapeutics Inc at approximately $6.8M (range $110K–$53M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.10× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 12.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 25% of Biotechnology peers (4293 compared).
Modeled value ranks above 13% of those peers.
Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.